HK1258128A1 - 选择病人接受组合疗程 - Google Patents

选择病人接受组合疗程 Download PDF

Info

Publication number
HK1258128A1
HK1258128A1 HK19100418.3A HK19100418A HK1258128A1 HK 1258128 A1 HK1258128 A1 HK 1258128A1 HK 19100418 A HK19100418 A HK 19100418A HK 1258128 A1 HK1258128 A1 HK 1258128A1
Authority
HK
Hong Kong
Prior art keywords
combination therapy
patients
selection
entinostat
methods
Prior art date
Application number
HK19100418.3A
Other languages
English (en)
Chinese (zh)
Inventor
Peter Ordentlich
Original Assignee
Syndax Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Syndax Pharmaceuticals Inc. filed Critical Syndax Pharmaceuticals Inc.
Publication of HK1258128A1 publication Critical patent/HK1258128A1/zh

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A61K31/5685—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone having an oxo group in position 17, e.g. androsterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • G01N33/56972—White blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
HK19100418.3A 2015-09-02 2016-09-02 选择病人接受组合疗程 HK1258128A1 (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562213288P 2015-09-02 2015-09-02
US201562213288P 2015-09-02
US201562219612P 2015-09-16 2015-09-16
US201562219612P 2015-09-16
PCT/US2016/050274 WO2017041043A1 (en) 2015-09-02 2016-09-02 Selection of patients for combination therapy

Publications (1)

Publication Number Publication Date
HK1258128A1 true HK1258128A1 (zh) 2019-11-08

Family

ID=58188549

Family Applications (1)

Application Number Title Priority Date Filing Date
HK19100418.3A HK1258128A1 (zh) 2015-09-02 2016-09-02 选择病人接受组合疗程

Country Status (14)

Country Link
US (2) US11397184B2 (cg-RX-API-DMAC10.html)
EP (1) EP3345002A4 (cg-RX-API-DMAC10.html)
JP (2) JP2018527570A (cg-RX-API-DMAC10.html)
KR (2) KR20240017973A (cg-RX-API-DMAC10.html)
CN (2) CN116893262A (cg-RX-API-DMAC10.html)
AU (2) AU2016318136B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018003238A2 (cg-RX-API-DMAC10.html)
CA (1) CA2994731C (cg-RX-API-DMAC10.html)
HK (1) HK1258128A1 (cg-RX-API-DMAC10.html)
IL (1) IL257355B (cg-RX-API-DMAC10.html)
MX (1) MX2018002640A (cg-RX-API-DMAC10.html)
RU (1) RU2018111407A (cg-RX-API-DMAC10.html)
WO (1) WO2017041043A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201800931B (cg-RX-API-DMAC10.html)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2016235434B2 (en) * 2015-03-20 2022-02-03 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer
BR112018015291A2 (pt) 2016-01-28 2018-12-18 Univ Indiana Res & Tech Corp uso de inibidores de histona desacetilase para melhorar imunoterapias
TWI794171B (zh) 2016-05-11 2023-03-01 美商滬亞生物國際有限公司 Ｈｄａｃ抑制劑與ｐｄ-ｌ１抑制劑之組合治療
TWI808055B (zh) 2016-05-11 2023-07-11 美商滬亞生物國際有限公司 Hdac 抑制劑與 pd-1 抑制劑之組合治療
EP4650005A3 (en) 2016-07-15 2026-01-28 Viracta Subsidiary, Inc. Histone deacetylase inhibitors for use in immunotherapy
US12168054B2 (en) 2017-05-19 2024-12-17 Syndax Pharmaceuticals, Inc. Method of treating cancer using a combination of entinostat and an anti-CSF-1R antibody
CN112513636A (zh) * 2018-05-07 2021-03-16 赛达克斯制药股份有限公司 用于组合疗法的患者的选择
CN109251891B (zh) * 2018-09-21 2021-10-22 苏州大学附属第一医院 一种cd40联合pd-l1及细胞因子扩增pbmc的方法
CN117054649A (zh) * 2023-08-04 2023-11-14 广州中医药大学第一附属医院 一种慢性萎缩性胃炎向胃癌转化标志物及其应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4328245A (en) 1981-02-13 1982-05-04 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4410545A (en) 1981-02-13 1983-10-18 Syntex (U.S.A.) Inc. Carbonate diester solutions of PGE-type compounds
US4409239A (en) 1982-01-21 1983-10-11 Syntex (U.S.A.) Inc. Propylene glycol diester solutions of PGE-type compounds
US6350458B1 (en) 1998-02-10 2002-02-26 Generex Pharmaceuticals Incorporated Mixed micellar drug deliver system and method of preparation
ITUD20080058A1 (it) * 2008-03-18 2009-09-19 Thankstem S R L Kit per la raccolta di sangue, preferibilmente periferico, per la produzione di cellule staminali
GB201015765D0 (en) * 2010-09-21 2010-10-27 Immatics Biotechnologies Gmbh Use of myeloid cell biomarkers for the diagnosis of cancer
WO2012149416A2 (en) * 2011-04-28 2012-11-01 University Of Southern California Human myeloid derived suppressor cell cancer markers
GEP201706612B (en) 2011-09-02 2017-02-10 Novamedica Llc Methods for the treatment of breast cancer
WO2014011713A2 (en) 2012-07-10 2014-01-16 Dana-Farber Cancer Institue, Inc. Anti-proliferative compounds and uses thereof
WO2014085461A1 (en) 2012-11-29 2014-06-05 The Penn State Research Foundation Photodynamic dhsip anticancer therapeutic and immunomodulator
JP6626085B2 (ja) 2014-07-15 2019-12-25 ザ・ジョンズ・ホプキンス・ユニバーシティー 骨髄由来抑制細胞の抑制及び免疫チェックポイント阻害の方法
AU2016235434B2 (en) * 2015-03-20 2022-02-03 Syndax Pharmaceuticals, Inc. Combination of HDAC inhibitor and anti-PD-1 antibody for treatment of cancer

Also Published As

Publication number Publication date
CN108139403A (zh) 2018-06-08
CA2994731A1 (en) 2017-03-09
RU2018111407A (ru) 2019-10-03
ZA201800931B (en) 2023-12-20
CA2994731C (en) 2023-09-26
IL257355A (en) 2018-04-30
US20180252721A1 (en) 2018-09-06
JP2018527570A (ja) 2018-09-20
EP3345002A1 (en) 2018-07-11
US20230061048A1 (en) 2023-03-02
AU2022246409A1 (en) 2022-11-03
KR102631377B1 (ko) 2024-01-29
WO2017041043A1 (en) 2017-03-09
AU2016318136A1 (en) 2018-02-22
MX2018002640A (es) 2018-06-20
KR20180048703A (ko) 2018-05-10
IL257355B (en) 2021-10-31
EP3345002A4 (en) 2019-05-08
AU2016318136B2 (en) 2022-10-20
JP2022009460A (ja) 2022-01-14
JP7206352B2 (ja) 2023-01-17
RU2018111407A3 (cg-RX-API-DMAC10.html) 2020-02-10
CN108139403B (zh) 2023-05-09
US11397184B2 (en) 2022-07-26
CN116893262A (zh) 2023-10-17
KR20240017973A (ko) 2024-02-08
BR112018003238A2 (en) 2018-09-25

Similar Documents

Publication Publication Date Title
ZA201800931B (en) Selection of patients for combination therapy
EA201691866A1 (ru) Проникающие в опухоль лимфоциты для адоптивной клеточной терапии
BR112018067368A2 (pt) terapia de combinação com anticorpos anti-cd73
BR112017010761A2 (pt) tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia
PH12017502154A1 (en) Methods for conditioning patients for t cell therapy
PH12017502153A1 (en) Diagnostic methods for t cell therapy
MX2018002723A (es) Macrociclicos peptidomimeticos y usos de los mismos.
EP3229586A4 (en) Genetically modified cells, tissues, and organs for treating disease
EP3131931A4 (en) Methods for increasing red blood cell levels and treating sickle-cell disease
MY192999A (en) Combination therapy of t cell activating bispecific antigen binding molecules and pd-1 axis binding antagonists
MX2015014486A (es) Marcadores de respuesta de células tumorales a la terapia.
BR112018008390A2 (pt) composições e métodos para transdução tumoral
EP3135374A4 (en) Ion exchange membrane, ion exchange membrane laminated body provided with ion exchange membrane, electrochemical cell provided with ion exchange membrane laminated body, and water treatment apparatus provided with electrochemical cell
HK1221424A1 (zh) 治疗癌症的药物组合
EP4286847A3 (en) Genetic abnormalities in plasma cell dyscrasias
EP3273977A4 (en) Nk-92 cells in combination therapy with cancer drugs
EP3266865A4 (en) Cell therapeutic agent for cancer treatment and combination therapy with same
SG11202101071WA (en) Proton therapy gantry
SG11202007414XA (en) Osimertinib for use in the treatment of non-small cell lung cancer
WO2018009904A3 (en) Compositions and treatment methods for cancer immunotherapy
EP3314250A4 (en) Cancer therapy targeting tetraspanin 33 (tspan33) in myeloid derived suppressor cells
WO2016130581A3 (en) Combination cancer therapy
HK1257882A1 (zh) 通过t细胞疗法来治疗多发性骨髓瘤和浆细胞性白血病的方法
WO2015042446A3 (en) Compositions and methods for the analysis of radiosensitivity
EP3490674A4 (en) ALPHA-SYNUCLEIN IN MONONUCLEAR CELLS OF PERIPHERAL BLOOD AS A BIOMARKER FOR SYNUCLEINOPATHY.

Legal Events

Date Code Title Description
AM Amended specification (according sect 146 of patent law)

Free format text: CORRECTION OF THE ENGLISH NAME OF THE APPLICANT

Effective date: 20250516